HC Wainwright Reaffirms Buy Rating for Femasys (NASDAQ:FEMY)

Femasys (NASDAQ:FEMY)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a research note issued on Thursday,Benzinga reports. They presently have a $12.00 target price on the stock.

Separately, Chardan Capital decreased their price objective on shares of Femasys from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, November 13th.

Femasys Trading Down 1.0 %

Shares of FEMY stock traded down $0.02 on Thursday, hitting $1.45. 6,008,943 shares of the company’s stock traded hands, compared to its average volume of 268,376. The stock has a market capitalization of $33.09 million, a price-to-earnings ratio of -1.78 and a beta of -2.86. The company’s fifty day simple moving average is $1.30 and its 200 day simple moving average is $1.19. Femasys has a one year low of $0.86 and a one year high of $2.12. The company has a debt-to-equity ratio of 0.86, a quick ratio of 3.26 and a current ratio of 3.94.

Hedge Funds Weigh In On Femasys

Institutional investors have recently bought and sold shares of the stock. Virtu Financial LLC purchased a new stake in shares of Femasys during the 4th quarter worth approximately $25,000. Aljian Capital Management LLC bought a new position in shares of Femasys in the 3rd quarter valued at about $27,000. Jane Street Group LLC purchased a new position in Femasys in the fourth quarter worth about $30,000. XTX Topco Ltd raised its position in Femasys by 123.9% during the third quarter. XTX Topco Ltd now owns 32,535 shares of the company’s stock valued at $36,000 after purchasing an additional 18,004 shares during the period. Finally, Citadel Advisors LLC purchased a new position in shares of Femasys in the 4th quarter worth approximately $45,000. 65.27% of the stock is owned by hedge funds and other institutional investors.

Femasys Company Profile

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.